NASDAQ | TSX: ACB
- Re-Affirms Commitment to Achieving Positive Free Cash Flow1 This Calendar Year, Delivers Fifth Consecutive Quarter of Positive Adjusted EBITDA1
- Aurora Becomes the Largest Global Medical Cannabis Company in Nationally Legal Markets Following the Acquisition of MedReleaf Australia
- Strong YoY Growth of 41% in High Margin International Net Cannabis Revenue1
- Cash position of over $200 Million as of Quarter Close, Remaining Convertible Debt of $7.3 Million to be Fully Repaid in February
EDMONTON, AB, Feb. 8, 2024 /PRNewswire/ – Aurora Cannabis Inc. (the “Company” or “Aurora”) (NASDAQ: ACB) (TSX: ACB), the Canada-based leading global medical cannabis company, today announced its financial and operational results for the third quarter of fiscal year 2024. As the fiscal year 2023 consisted of three quarters, the year-over-year comparison quarter for Q3 2024 ending December 31, 2023, is Q2 2023 ending
